<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32558326</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>10</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1942-7611</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug testing and analysis</Title>
          <ISOAbbreviation>Drug Test Anal</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Detection of bioactive peptides including gonadotrophin-releasing factors (GnRHs) in horse urine using ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC/HRMS).</ArticleTitle>
        <Pagination>
          <StartPage>1274</StartPage>
          <EndPage>1286</EndPage>
          <MedlinePgn>1274-1286</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/dta.2880</ELocationID>
        <Abstract>
          <AbstractText>The use of bioactive peptides as a doping agent in both human and animal sports has become increasingly popular in recent years. As such, methods to control the misuse of bioactive peptides in equine sports have received attention. This paper describes a sensitive accurate mass method for the detection of 40 bioactive peptides and two non-peptide growth hormone secretagogues (&lt; 2 kDa) at low pg/mL levels in horse urine using ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC/HRMS). A simple mixed-mode cation exchange solid-phase extraction (SPE) cartridge was employed for the extraction of 42 targets and/or their in vitro metabolites from horse urine. The final extract was analyzed using UHPLC/HRMS in positive electrospray ionization (ESI) mode under both full scan and data independent acquisition (DIA, for MS<sup>2</sup> ). The estimated limits of detection (LoD) for most of the targets could reach down to 10 pg/mL in horse urine. This method was validated for qualitative detection purposes. The validation data, including method specificity, method sensitivity, extraction recovery, method precision, and matrix effect were reported. A thorough in vitro study was also performed on four gonadotrophin-releasing factors (GnRHs), namely leuprorelin, buserelin, goserelin, and nafarelin, using the S9 fraction isolated from horse liver. The identified in vitro metabolites have been incorporated into the method for controlling the misuse of GnRHs. The applicability of this method was demonstrated by the identification of leuprorelin and one of its metabolites, Leu M4, in urine obtained after intramuscular administration of leuprorelin to a thoroughbred gelding (castrated horse).</AbstractText>
          <CopyrightInformation>© 2020 John Wiley &amp; Sons, Ltd.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kwok</LastName>
            <ForeName>Karen Y</ForeName>
            <Initials>KY</Initials>
            <Identifier Source="ORCID">0000-0002-0839-8987</Identifier>
            <AffiliationInfo>
              <Affiliation>Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T, Hong Kong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Choi</LastName>
            <ForeName>Timmy L S</ForeName>
            <Initials>TLS</Initials>
            <Identifier Source="ORCID">0000-0001-6091-251X</Identifier>
            <AffiliationInfo>
              <Affiliation>Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T, Hong Kong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kwok</LastName>
            <ForeName>Wai Him</ForeName>
            <Initials>WH</Initials>
            <Identifier Source="ORCID">0000-0001-5239-7079</Identifier>
            <AffiliationInfo>
              <Affiliation>Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T, Hong Kong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lau</LastName>
            <ForeName>Ming Yip</ForeName>
            <Initials>MY</Initials>
            <AffiliationInfo>
              <Affiliation>Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T, Hong Kong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leung</LastName>
            <ForeName>Elvis M K</ForeName>
            <Initials>EMK</Initials>
            <AffiliationInfo>
              <Affiliation>Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T, Hong Kong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Leung</LastName>
            <ForeName>Gary N W</ForeName>
            <Initials>GNW</Initials>
            <Identifier Source="ORCID">0000-0002-6949-5721</Identifier>
            <AffiliationInfo>
              <Affiliation>Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T, Hong Kong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wong</LastName>
            <ForeName>Jenny K Y</ForeName>
            <Initials>JKY</Initials>
            <Identifier Source="ORCID">0000-0001-8245-6770</Identifier>
            <AffiliationInfo>
              <Affiliation>Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T, Hong Kong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wan</LastName>
            <ForeName>Terence S M</ForeName>
            <Initials>TSM</Initials>
            <Identifier Source="ORCID">0000-0003-3779-2649</Identifier>
            <AffiliationInfo>
              <Affiliation>Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T, Hong Kong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Adrian</LastName>
            <ForeName>Farrington F</ForeName>
            <Initials>FF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Veterinary Clinical Services, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T, Hong Kong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Prabhu</LastName>
            <ForeName>Anil</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Veterinary Regulation, Welfare and Biosecurity Policy, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T, Hong Kong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ho</LastName>
            <ForeName>Emmie N M</ForeName>
            <Initials>ENM</Initials>
            <Identifier Source="ORCID">0000-0001-8366-2066</Identifier>
            <AffiliationInfo>
              <Affiliation>Racing Laboratory, The Hong Kong Jockey Club, Sha Tin Racecourse, Sha Tin, N.T, Hong Kong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D023361">Validation Study</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>07</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Drug Test Anal</MedlineTA>
        <NlmUniqueID>101483449</NlmUniqueID>
        <ISSNLinking>1942-7603</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010455">Peptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>33515-09-2</RegistryNumber>
          <NameOfSubstance UI="D007987">Gonadotropin-Releasing Hormone</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EFY6W0M8TG</RegistryNumber>
          <NameOfSubstance UI="D016729">Leuprolide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004300" MajorTopicYN="N">Doping in Sports</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007987" MajorTopicYN="N">Gonadotropin-Releasing Hormone</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
          <QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006736" MajorTopicYN="N">Horses</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016729" MajorTopicYN="N">Leuprolide</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
          <QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057230" MajorTopicYN="N">Limit of Detection</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName>
          <QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D052616" MajorTopicYN="N">Solid Phase Extraction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015813" MajorTopicYN="N">Substance Abuse Detection</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">bioactive peptides</Keyword>
        <Keyword MajorTopicYN="N">gonadotrophin-releasing factors (GnRHs)</Keyword>
        <Keyword MajorTopicYN="N">high resolution mass spectrometry (HRMS)</Keyword>
        <Keyword MajorTopicYN="N">in vitro biotransformation</Keyword>
        <Keyword MajorTopicYN="N">ultra-high performance liquid chromatography (UHPLC)</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32558326</ArticleId>
        <ArticleId IdType="doi">10.1002/dta.2880</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Fields K, Falla TJ, Rodan K, Bush L. Bioactive peptides: signaling in the future. J Cosmet Dermatol. 2009;8(1):8-13.</Citation>
        </Reference>
        <Reference>
          <Citation>Fosgerau K, Hoffman T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20(1):122-128.</Citation>
        </Reference>
        <Reference>
          <Citation>Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs. Chem Biol Drug Des. 2013;81(1):136-147.</Citation>
        </Reference>
        <Reference>
          <Citation>Sato AK, Viswanathan M, Kent RB, Wood CR. Therapeutic peptides: technological advances driving peptides into development. Curr Opin Biotechnol. 2006;17(6):638-642.</Citation>
        </Reference>
        <Reference>
          <Citation>Smith RG. Development of growth hormone secretagogues. Endocr Rev. 2005;26(3):346-360.</Citation>
        </Reference>
        <Reference>
          <Citation>Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. Eur J Endocrinol. 1997;136(5):445-460.</Citation>
        </Reference>
        <Reference>
          <Citation>Sanchis-Gomar F, Martinez-Bello VE, Nascimento AL, et al. Desmopressin and hemodilution: implications in doping. Int J Sports Med. 2010;31(1):5-9.</Citation>
        </Reference>
        <Reference>
          <Citation>Broccardo M, Erspamer V, Falconieri G, et al. Pharmacological data on dermorphins, a new class of potent opioid peptides from amphibian skin. Br J Pharmocol. 1981;73:625-631.</Citation>
        </Reference>
        <Reference>
          <Citation>Negri L, Lattanzi R, Melchiorri P. Production of antinociception by peripheral administration of [Lys]dermorphin, a naturally occurring peptide with high affinity for mu-opioid receptors. Br J Pharmocol. 1995;114:57-66.</Citation>
        </Reference>
        <Reference>
          <Citation>World Anti-Doping Agency (WADA). The 2020 prohibited list - international standard. Available at: https://www.wada-ama.org/sites/default/files/wada_2020_english_prohibited_list_0.pdf [Accessed on 17 Jan 2020]</Citation>
        </Reference>
        <Reference>
          <Citation>International Federation of Horseracing Authorities (IFHA). Article 6E, International Agreement on Breeding, Racing and Wagering (IABRW). Available at: https://www.ifhaonline.org/resources/ifAgreement.pdf [Accessed on 17 Jan 2020]</Citation>
        </Reference>
        <Reference>
          <Citation>World Anti-Doping Agency (WADA). 2018 Anti-Doping Testing Figures Report. Available at: https://www.wada-ama.org/sites/default/files/resources/files/2018_testing_figures_report.pdf [Accessed on 17 Jan 2020]</Citation>
        </Reference>
        <Reference>
          <Citation>Ho ENM, Kwok WH, Wong ASY, Wan TSM. Doping control analysis of TB500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography/mass spectrometry. J Chromatogr A. 2012;1265:57-69.</Citation>
        </Reference>
        <Reference>
          <Citation>Kwok WH, Ho ENM, Lau MY, Leung GNW, Wong ASY, Wan TSM. Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry. Anal Bioanal Chem. 2013;405(8):2595-2606.</Citation>
        </Reference>
        <Reference>
          <Citation>Leung GNW, Choi TLS, Kwok WH, Lau MY, Wong JKY, Wan TSM. Doping control analysis of bioactive peptides in equine urine and plasma by liquid chromatography - high resolution mass spectrometry. In: Proceedings of 20th International Conference of Racing Analysts and Veterinarians (ICRAV); 2015:114-124.</Citation>
        </Reference>
        <Reference>
          <Citation>Mazzarino M, Calvaresi V, de la Torre X, Parrotta G, Sebastianelli C, Botrè F. Development and method validation of a liquid chromatography-mass spectrometry procedure after solid phase extraction for detection of 19 doping peptides in human urine. Forensic Toxicol. 2015;33:321-337.</Citation>
        </Reference>
        <Reference>
          <Citation>Steel R, Timms M, Levina V, Vine J. A high throughput screen for 17 dermorphin peptides in equine and human urine and equine plasma. Drug Test Anal. 2014;6(9):909-921.</Citation>
        </Reference>
        <Reference>
          <Citation>Guan F, Robinson MA. Comprehensive solid-phase extraction of multitudinous bioactive peptides from equine plasma and urine for doping detection. Anal Chim Acta. 2017;8:79-90.</Citation>
        </Reference>
        <Reference>
          <Citation>Timms M, Hall N, Levina L, Vine J, Steel R. A high throughput LC-MS/MS screen for GHRP in equine and human urine, featuring peptide derivatization for improved chromatography. Drug Test Anal. 2014;6(10):985-995.</Citation>
        </Reference>
        <Reference>
          <Citation>Semenistaya E, Zvereva I, Krotov G, Rodchenkov G. Solid-phase extraction of small biologically active peptides on cartridges and microelution 96-well plates from human urine. Drug Test Anal. 2015;8:940-949.</Citation>
        </Reference>
        <Reference>
          <Citation>Thomas A, Görgens C, Guddat S, et al. Simplifying and expanding the screening for peptides &lt; 2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry. J Sep Sci. 2016;39(2):333-341.</Citation>
        </Reference>
        <Reference>
          <Citation>Judák P, Grainger J, Goebel C, Van Eenoo P, Deventer K. DMSO assisted electrospray ionization for the detection of small peptide hormones in urine by dilute-and-shoot-liquid-chromatography-high resolution mass spectrometry. J Am Soc Mass Spectrom. 2017;28(8):1657-1665.</Citation>
        </Reference>
        <Reference>
          <Citation>Sardela VF, Martucci MEP, de Araújo ALD, et al. Comprehensive analysis by liquid chromatography-Q-Orbitrap mass spectrometry: fast screening of peptides and organic molecules. J Am Soc Mass Spectrom. 2018;53:476-503.</Citation>
        </Reference>
        <Reference>
          <Citation>Handelsman DJ, Idan A, Grainger J, Goebel C, Turner L, Conway AJ. Detection and effects on serum and urine steroid and LH of repeated GnRH analog (leuprolide) stimulation. J Steroid Biochem Mol Biol. 2014;141:113-120.</Citation>
        </Reference>
        <Reference>
          <Citation>Wong JKY, Tang FPW, Wan TSM. In vitro metabolic studies using homogenised horse liver in place of horse liver microsomes. Drug Test Anal. 2011;3(6):393-399.</Citation>
        </Reference>
        <Reference>
          <Citation>Zvereva I, Dudko G, Dikunets M. Determination of GnRH and its synthetic analogues’ abuse in doping control: small bioactive peptide UPLC-MS/MS method extension by addition of in vitro and in vivo metabolism data; evaluation of LH and steroid profile parameter fluctuations as suitable maker. Drug Test Anal. 2018;10(4):711-722.</Citation>
        </Reference>
        <Reference>
          <Citation>Palmer D, Rademaker K, Martin I, Hessell J, Howitt R. Identification of gonadotropin-releasing hormone metabolites in greyhound urine. Drug Test Anal. 2017;9:1499-1505.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
